新型 DES 和 BVS 血栓发生现状及应对策略 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
|
|
- Vivien McCarthy
- 5 years ago
- Views:
Transcription
1 新型 DES 和 BVS 血栓发生现状及应对策略 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 OCC2016
2 Increase of LST and death for first generation DES after stop of 6m DAPT
3 BASKET-LATE Study P< m FU Pfisterer M, et al. J Am Coll Cardiol. 2006;48(12):
4 Current ST status of 1st DES Outcomes associated with drug-eluting and baremetal stents: a collaborative network meta-analysis 27 trials provide data on definite stent thrombosis according to ARC criteria. 1-4 years FU Stettler C, et al. Lancet. 2007;370:
5 TAXUS CYPHER BMS Stettler C, et al. Lancet. 2007;370:
6 Current ST status of new generation of DES TAXUS ENDEAVOR XIENCE CYPHER Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis RESOLUTE PROMUS ELEMENT Palmerini T, et al. Lancet. 2012;379:
7 1-year definite ST was significantly lower with CoCr-EES than with BMS and PES, even lower than with Resolute. At 2-year follow-up, CoCr-EES were still associated with significantly lower rates of definite ST than BMS and PES. No other DES had lower definite ST rates compared with BMS at 2-year follow-up. Palmerini T, et al. Lancet. 2012;379:
8 Current ST status of BVS Acute ST 0.27% Subacute ST 0.57% late Very Late acute This may reflect an increase in the studies using BVS in patients with ACS. Lipinski M, et al. JACC Cardiovasc Interv. 2016;9: Puricel S, et al. J Am Coll Cardiol. 2016;67:
9 Lipinski M, et al. JACC Cardiovasc Interv. 2016;9:12-24.
10 Cause of DES ST Compliance With Antithrombotic Regimens at the Time of Stent Thrombosis Waksman R, et al. JACC Cardiovasc Interv. 2014;7(10): Holmes DR Jr, et al. J Am Coll Cardiol. 2010;56(17): Urban P, et al. J Am Coll Cardiol. 2011;57:
11 OCT analysis of ST dissection malapposition Uncovered struts neoatherosclerosis Ruptured neoatherosclerosis Ruptured neoatherosclerosis Souteyrand G, et al. Eur Heart J. 2016;37(15):
12 Cause of BVS ST Similar to DES, ST is a particularly severe complication whose 12- month incidence was as high as 3%. None of the clinical characteristics was an independent predictor of ST. QCA features of small vessels were a hallmark of ST. Suboptimal post-procedural angiographic results, with even small deviations from the nominal BVS diameter, were associated with exponential increases in the risk of ST. The curve describing the positive predictive values of different post-procedural MLDs showed a steeper increase for values <2.4/2.8 mm. MLD values <2.1 mm (for the 2.5-/3.0-mm BVS) and 2.7 mm (for the 3.5-mm BVS) were associated with ST with a specificity of 90% and a sensitivity of 50%. Puricel S, et al. J Am Coll Cardiol. 2016;67:
13 ST risk assessment and prevention Patient, lesion, and stent selection Risk score calculation Technique DAPT compliance and interruption Claessen BE, et al. JACC Cardiovasc Interv. 2014;7(10):
14 Patient, lesion, and stent selection BMS lesion with low risk of restenosis and patients at increased risk of bleeding, scheduled for surgery, allergic to thienopyridines, and/or in whom compliance is questionable. New generation of DES (XIENCE, RESOLUTE, and PROMUS ELEMENT) provide the best combination of safety and efficacy. Fully bioabsorbable scaffold may reduce very late stent thrombosis, but long-term results of large-scale trials investigating the safety and efficacy are not yet available.
15 Risk score calculation Dangas GD, et al. JACC Cardiovasc Interv. 2012;5:
16 Low risk of ST intermediate High risk of ST Dangas GD, et al. JACC Cardiovasc Interv. 2012;5:
17 Technique Optimize the results of procedure Proper stent expansion and apposition Avoid residual dissection IVUS guided stent implantation Stent length, excessive use of stents is discouraged Provisional side-branch stenting approach might be preferable to routine CRUSH or CULOTTE stenting in bifurcation lesion
18 DAPT Recommendation Binder RK, et al. Eur Heart J. 2015;36(20):
19 MACCE and DAPT duration Low bleeding risk 6 months 12 months 30 months Intermediate Favor long DAPT OPTIMIZE RESET EXCELLENT PRODIGY ITALIC DES LATE DAPT OPTIMIZE RESET EXCELLENT PRODIGY ITALIC DES LATE DAPT Short DAPT Individualized DAPT management Low ischemic risk Long DAPT P< Bleeding and DAPT duration Intermediate 2.9 ischemic risk 2.3 Short DAPT = 3-12m Long DAPT = 12-36m Short DAPT High ischemic risk P=0.004 bleeding risk 3-6 months 6-12 months 12 months Long DAPT High bleeding risk 3 months 3-6 months 6-12 months P= Binder RK, et al. Eur Heart J. 2015;36(20): Palmerini T, Lancet. 2015;385(9985):
20 A DAPT score is recommended. A score of 2 is associated with a favorable benefit/risk ratio for prolonged DAPT while a score of <2 is associated with an unfavorable benefit/risk ratio.
21 2016 新指南对双抗疗程管理的推荐 : 依据疾病类型 再灌注方法和缺血及出血风险 CAD SIHD 急性 / 近期 ACS (NSTE-ACS 或 STEMI) 无 PCI 史或近期 CABG S/P PCI S/P CABG 药物治疗 溶栓 (STEMI) PCI (BMS 或 DES) CABG BMS DES 0 个月 6 个月 12 个月 III 类 : 无获益 I 类 : 至少 1 个月 ( 氯吡格雷 ) I 类 : 至少 6 个月 ( 氯吡格雷 ) 无出血高风险及明显出血 IIb 类 : >1 个月是合理的 IIb 类 : >6 个月是合理的 IIb 类 : 12 个月是合理的 ( 氯吡格雷 ) I 类 : 至少 12 个月 ( 氯吡格雷 替格瑞洛 ) I 类 : 最少 14 天, 理想情况下为至少 12 个月 ( 氯吡格雷 ) I 类 : 至少 12 个月 ( 氯吡格雷 普拉格雷 替格瑞洛 ) I 类 : CABG 术后继续接受 P2Y12 抑制剂治疗, 以完成 1 年 DAPT 无出血高风险及明显出血 IIb 类 :>12 个月是合理的 图底部的箭头表示延长 DAPT 的最佳疗程并不确定 Levine GN, et al. J Am Coll Cardiol Mar 23. pii: S (16)
22 Take home messages ST of new generation of DES is lower than 1 st DES, even lower than BMS. BVS may reduce very late ST, but long-term results are not yet available. Carefully selection of patient, lesion and stent may reduce the occurrence of ST. Optimize the results of PCI. Individualized DAPT is recommended.
23 Thank You!
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationDefinition of Stroke ( 中风 )
Definition of Stroke ( 中风 ) Sudden brain damage Lack of blood flow to the brain caused by a clot or rupture of a blood vessel Ischemia = Clot 缺血 (makes up approximately 87% of all strokes) Embolic Thrombotic
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationMałgorzata Golik. Physiotherapist, certified, master s degree physiotherapist, neurological disorders specialist
全身运动反馈系统在波兰和欧洲的应用 Małgorzata Golik Physiotherapist, certified, master s degree physiotherapist, neurological disorders specialist Graduation: Warsaw Academy of Physical Activity and Education, Poland Poland
More information宫颈上皮内瘤变 ; IgG1 IgG2 亚类 ; 酶联免疫吸附试验 R A (2009)
2009 年第 19 卷第 11 期 CHINA ONCOLOGY 2009 Vol.19 No.11 831 免疫球蛋白 G(immunoglobulin G,IgG) 是血清和细胞外液中含量最高的免疫球蛋白, 其某个亚类的升高, 可能与宫颈上皮内瘤变 (cervical intraepithelial neoplasia, CIN) 的发生 发展及转归有密切相关 然而对于 CIN 患者血清人乳头瘤病毒样颗粒
More information读书报告 2015 年 月 唐之韵
读书报告 2015 年 03-04 月 唐之韵 Mar. Apr. NEJM VOL.372 Kaukonen KM1, Bailey M, Pilcher D, et al. N Engl J Med. 2015 Apr 23;372(17):1629-38. Systemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis.
More informationDevelopment of clinical trial for molecular targeted therapy in Breast Cancer
Development of clinical trial for molecular targeted therapy in Breast Cancer Ze-Fei Jiang 军事医学科学院附属医院 江泽飞 Cancer Drug Development: 1945 Present Total No. Approved Drugs 85 75 65 55 Ibritumomab/Tositumomab/Bortezomib
More information结构性心脏病介入治疗进展 周达新 复旦大学附属中山医院上海市心血管病研究所. Approaches to structural Heart Disease of Intervention
结构性心脏病介入治疗进展 Approaches to structural Heart Disease of Intervention 周达新 复旦大学附属中山医院上海市心血管病研究所 Interventional Cath for CHD In 1967 Porstmann helped develop the Ivalon plug and was the first to use it clinically.
More informationWhat s New in Antiplatelet Therapy and DES in 2016
What s New in Antiplatelet Therapy and DES in 2016 Peter Pollak MD Director of Structural Heart Disease & Intervention Mayo Clinic Florida 2016 slide-1 Disclosures Financial None Off-label - None 2016
More informationHypertension and cardiac arrhythmias
CardioPulse 223 doi:10.1093/eurheartj/ehw664 Hypertension and cardiac arrhythmias A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Council
More informationReceived Accepted This work was supported by the National Natural Science Foundation of China (No ).
Acta Physiologica Sinica, August 25, 2012, 64(4): 449 454 http://www.actaps.com.cn 449 Research Paper Involvement of protein kinase A activation and phospholipase A 2 inhibition in the adenosine-activated
More informationHow to Make the Choice?
How to Make the Choice? Translational Approach for Cancer Treatment 闻丹忆 Danyi.wen@lidebiotech.com 181 9229 52 Nov 23, 214 1 Tumor volume (mm 3 ) Tumor growth (Efficacy study in LIX4-FP1+2) 15 Vehiclel,
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More information500 中国肺癌杂志2010年5月第13卷第5期 C h i n J L u n g C a n c e r, M ay , Vo l. 1 3, No. 5 临床研究 血清TPS CEA Pro-GRP和CYFRA21-1 水平在肺癌患者中的临床意义 王敬慧 时广利 张树才 王群慧
5 临床研究 血清 和CYFRA- 水平在肺癌患者中的临床意义 王敬慧 时广利 张树才 王群慧 杨新杰 李曦 王海永 张卉 宋长兴 摘要 背景与目的 血清肿瘤标志物在肺癌的诊断 疗效 预后判断中起着重要作用 本研究探讨血清组 织多肽特异性抗原 tissue polypeptide specific antigen, 与癌胚抗原 carcinoembryonic antigen, 胃泌素释放 肽前体
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More information中国 HIV 新发感染检测发展及未来 Development and Future of HIV-1 Incidence Assay in China
中国 HIV 新发感染检测发展及未来 Development and Future of HIV-1 Incidence Assay in China Yan Jiang MD, PhD. National HIV Reference Laboratory, China CDC 中国 HIV 检测体系 HIV Testing in China Screening Confirmatory Recent
More informationHow to Predict & Prevent It! George D. Dangas, MD, FACC, FESC
Stent Thrombosis How to Predict & Prevent It! George D. Dangas, MD, FACC, FESC Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Καθηγητής Καρδιολογίας ΕΚΠΑ
More informationDAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders
DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationA Case Report on Primary Ovarian Leiomyo-Sarcoma and Some Related Documents Review
Asian Case Reports in Oncology 亚洲肿瘤科病例研究, 2013, 2, 11-15 http://dx.doi.org/10.12677/acrpo.2013.23004 Published Online July 2013 (http://www.hanspub.org/journal/acrpo.html) A Case Report on Primary Ovarian
More informationAffiliation/Financial Relationship
The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information老年与中青年急性呼吸窘迫综合征患者的特点及预后相关危险因素分析
794 中华危重病急救医学 2014 年 11 月第 26 卷第 11 期 Chin Crit Care Med,November 2014,Vol.26,No.11 论著 老年与中青年急性呼吸窘迫综合征患者的特点及预后相关危险因素分析 摘要 目的比较重症监护病房 (ICU) 内老年及中青年急性呼吸窘迫综合征 (ARDS) 患者的临床特点及预后相关危险因素 方法回顾性分析 2011 年 8 月至 2013
More informationHealth: Acupuncture in the UK 健康 : 针灸在英国
Health: Acupuncture in the UK 健康 : 针灸在英国 1 Health: Acupuncture in the UK 健康 : 针灸在英国 A Better Way to Beat Back Pain? 腰疼有救吗? What is the single largest cause of sick leave in the UK? The answer is not the
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationStents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationEGFR-TKI 治疗肺癌耐药的对 策和困境 上海市肺科医院肿瘤科 周彩存
EGFR-TKI 治疗肺癌耐药的对 策和困境 上海市肺科医院肿瘤科 周彩存 Chemotherapy for advanced NSCLC 0 25 50 75 100 MST (M) ORR (%) SWOG 9509 (N=410) PCAR VCIS 8.0 8.0 25 28 PCIS 8.1 21 ECOG 1594 (N=1163) GCIS DCIS 8.1 7.4 17 21 PCAR
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationAdd Your Company Slogan 损伤的修复. Repair of the injury 白求恩医学院病理教研室 Logo
Add Your Company Slogan 损伤的修复 白求恩医学院病理教研室 李 伟 2010.9.26 tissue and cellular injury Normal cells Adaptation irreversible injury reversible injury Adaptation hypertrophy hyperplasia atrophy metaplasia cellular
More informationTree shrew models: A chronic social defeat model of depression and a one-trial captive conditioning model of learning and memory
动物学研究 2011,Feb. 32(1): 24 30 CN 53-1040/Q ISSN 0254-5853 Zoological Research DOI:10.3724/SP.J.1141.2011.01024 Tree shrew models: A chronic social defeat model of depression and a one-trial captive conditioning
More information病毒基因组学与 病毒进化 刘翟博士研究员 中国科学院微生物研究所
病毒基因组学与 病毒进化 刘翟博士研究员 中国科学院微生物研究所 2016-6-27 新一代测序技术带来了测序成本的大大降低!!! $100,000,000 $10,000,000 Moore s Law $1,000,000 $100,000 $10,000 $1,000 $1,000 $100 Pathogens Genomics Pathogen infections are among the
More informationCross-sectional study on the relationship between life events and mental health of secondary school students in Shanghai, China
162 Shanghai Archives of Psychiatry, 2012, Vol.24, No.3 Cross-sectional study on the relationship between life events and mental health of secondary school students in Shanghai, China Linlin ZHOU, Juan
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More informationDNA-EGS1386 in cells induced RNase P inhibits the expression of human cytomegalovirus UL49 gene
生物工程学报 Chin J Biotech 2009, November 25; 25(11): 1690-1696 journals.im.ac.cn Chinese Journal of Biotechnology ISSN 1000-3061 cjb@im.ac.cn 2009 Institute of Microbiology, CAS & CSM, All rights reserved
More informationIntroduction CME. KY Lo *, CK Chan
CME Original Article Characteristics and outcomes of patients with percutaneous coronary intervention for unprotected left main coronary artery disease: a Hong Kong experience KY Lo *, CK Chan This article
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More information南京, 第十二届分子标志与核医学靶向诊断治疗大会, 心血管分子显像的进展 何作祥 国家心血管病中心国家心血管疾病临床医学研究中心心血管疾病国家重点实验室中国医学科学院阜外心血管病医院
南京, 第十二届分子标志与核医学靶向诊断治疗大会,2017.9.9 心血管分子显像的进展 何作祥 国家心血管病中心国家心血管疾病临床医学研究中心心血管疾病国家重点实验室中国医学科学院阜外心血管病医院 Molecular Imaging in Cardiovascular Diseases Evaluation of myocardial viability and ischemic memory Imaging
More informationConcurrent pulmonary thrombosis with systemic embolism: a case report *
838 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn Case Report:
More informationmalapposition assessed by OCT
Stent t coverage and malapposition assessed by OCT Myeong-Ki Hong, M.D. Ph D Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul,
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationJournal of Acupuncture and Tuina Science, 2012, v. 10 n. 2, p The original publication is available at
Title What is the origin of acupoint Author(s) Li, L; Yau, T; Yau, C Citation Journal of Acupuncture and Tuina Science, 2012, v. 10 n. 2, p. 125-127 Issued Date 2012 URL http://hdl.handle.net/10722/160714
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More informationAcute Glomerular Nephritis. Mao Jianhua, Department of Nephrology, The Children Hospital of Zhejiang University,
Acute Glomerular Nephritis Mao Jianhua, Department of Nephrology, The Children Hospital of Zhejiang University, maojh88@gmail.com DEFINITION APSGN is a immune-mediated inflammation disease with the mechanism
More informationBosworth, /1966. Clemmer, 1966 Driscoll McCorkle & Korn 1954 Ohlin 1956 Wheeler 1961 U U-shaped curve Wheeler
关于服刑人员适应监狱生活的经验性研究起源于 20 世纪的美国之后, 社 会学家开始用人类学方法研究, 然而在这些研究中, 关于女性服刑人员监狱适应的研究较 少, 并被当做男性服刑人员 附属物 来比较, 此后有学者开始关注监狱环境以及社会文化背 景对于女性服刑人员监狱适应性状况的影响本文通过回顾与反思认为, 对女性应从两个维 度即适应监狱制度环境和适应服刑人员群体或服刑人员亚文化入手并从中探讨两者间关
More information大舜政策研究中心 Dashun Policy Research Centre Ltd Annual Conference 2012
香港樂健會社 Happy Health Society in association with 大舜政策研究中心 Dashun Policy Research Centre Ltd Annual Conference 2012 人人健康由我做起 中西結合預防癌症 Prevention of Cancer East Meets West Approaches 2012 年 12 月 22 日 ( 星期六
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationInterferon-gamma and interleukin-10 levels in serum and saliva are related to different types of oral lichen planus
中国组织工程研究第 19 卷第 2 期 2015 01 08 出版 Chinese Journal of Tissue Engineering Research January 8, 2015 Vol.19, No.2 Interferon-gamma and interleukin-10 levels in serum and saliva are related to different types
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationDrug Eluting Stents: an update Abbott Vascular. All rights reserved.
Drug Eluting Stents: an update DES: Science and Education for Better Practice--Introduction The clinical benefits of DES in reducing the risk of restenosis are well established. Recently the safety profile
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationUpdate on AIDS in China
Update on AIDS in China Kong-Lai Zhang, MD Professor, Department of Epidemiology, Peking Union Medical College Beijing, CHINA March, 2013 1 HIV epidemic in Asia General Population Family Bridge Population
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationDiseases of the Urinary System. Wang Yishu Department of Pathology Basic Medical School
Diseases of the Urinary System Wang Yishu Department of Pathology Basic Medical School Introduction Anatomy and Histology of Urinary System Urinary System Kidney Bladder Ureter Urethra Functions of kidney
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationClinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD
Clinical Value of OCT Guidance for Coronary Stenting Giulio Guagliumi, MD 100 % Endovascular Imaging Indications of use 87.5 % 75 % 57.5 % 50 % 45 % 25 % 15 % 0 Lesion morphology Stent optimization Lesion
More informationUnit1 What s the matter? 东乌旗蒙中 --- 苏丽雅
Unit1 What s the matter? 东乌旗蒙中 --- 苏丽雅 body feet tooth teeth ear eye head face nose mouth head hand knee t leg foot finger healthy neck shoulder arm back sing a song 1a Look at the picture. Write the
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More information生物工程学报 Chin J Biotech 2009, July 25; 25(7): journals.im.ac.cn Chinese Journal of Biotechnology ISSN
生物工程学报 Chin J Biotech 2009, July 25; 25(7): 1035-1041 journals.im.ac.cn Chinese Journal of Biotechnology ISSN 1000-3061 cjb@im.ac.cn 2009 Institute of Microbiology, CAS & CSM, All rights reserved 医学与免疫生物技术
More information课程四 : 药物共晶 - 药物晶型开发的 新热点
晶云药物 2011 年第一届晶型专题技术培训 课程四 : 药物共晶 - 药物晶型开发的 新热点 主讲人 : 陈敏华博士, 首席执行官 Crystal Pharmatech 苏州晶云药物科技有限公司 Email:sales@crystalpharmatech.com 电话 :0512-69561921 1 提纲 药物共晶简介 为何要开发药物共晶? 共晶发展历史 共晶的定义和表征 形成共晶的方法 药物共晶的案例分析
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationDUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN
DUREE de la BITHERAPIE dans les ETUDES LEADERS J BERLAND Clinique Saint Hilaire ROUEN LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients
More information1. Original protocol, final protocol, summary of changes. (highlighted in. 2. Original statistical analysis plan, final statistical analysis plan,
Protocol This supplement contains the following items: 1. Original protocol, final protocol, summary of changes. (highlighted in yellow track change in the final protocol). 2. Original statistical analysis
More informationMetabolism Of Calcium and Phosphorus
Metabolism Of Calcium and Phosphorus Three hormones crucially involved: Vitamin D (1,25- (OH)2-D3) Parathyroid hormone (PTH) Calcitonin (CT) Calcium Is Needed For: Bone Matrix (70% CaOH in form of Hydroxyapatite)
More informationFractures of Extremities (Upper Limbs) Dr. Zhong gang. Department of Orthopaedic Surgery West China Hospital of Sichuan University
Fractures of Extremities (Upper Limbs) Dr. Zhong gang Department of Orthopaedic Surgery West China Hospital of Sichuan University 七 上肢骨折和手外伤 (Upper Limbs Fracture and Hand Injury) 一. 知识点与教学要求掌握 : 1. 肱骨干骨折,
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationI am glad to share my knowledge with you, and I want you to become a master of the subject, pharmacology Antiarrhythmic drugs 抗心律失常药 朱玲 四川大学华西医学中心 zhu
I am glad to share my knowledge with you, and I want you to become a master of the subject, pharmacology Antiarrhythmic drugs 抗心律失常药 朱玲 四川大学华西医学中心 zhuling529@163.com 教学要求 1. 了解心脏的电生理特性 2. 熟悉心律失常的发生机制 3.
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationCan Acupuncture Really benefit Stroke?
Can Acupuncture Really benefit Stroke? 朱氏头皮针介绍与中风治疗应用的讨论 朱明清 Ming Qing Zhu 蕭慕如 Moyee Siu 1 Strokes statistics 中风的统计 795,000 per year in USA; 50,000 in Canada 1 per 45 sec, 1 die every 4 min in USA 15 million
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationPharmaceutical Biotechnology 西安电子科技大学夏玉琼 Insulin and human growth hormone By Yuqiong Xia 5/19/2017
Pharmaceutical Biotechnology Insulin and human growth hormone By Yuqiong Xia 5/19/2017 生物技术制药 2 技术基础 生物技术药物 生物技术制药概念药物的开发药物的生产细胞因子生长因子激素类药物血液制品和治疗性酶抗体 疫苗和佐剂核酸药物 药物的发现 专利的申请临床前试验临床试验生物药物的来源生物药物的生产和纯化生物药物的分析干扰素白介素造血生长因子
More informationShedding light on stent thrombosis
Editorial Shedding light on stent thrombosis Tawfiq Choudhury 1,2, Rodrigo Bagur 1,2, Ashlay A. Huitema 1,2, Amir Solomonica 1,2, Shahar Lavi 1,2 1 Department of Medicine, Western University, London, ON,
More informationAntiplatelet Therapy After PCI: How Much and How Long?
Antiplatelet Therapy After PCI: How Much and How Long? Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Antiplatelet Therapy after PCI: How much and how long? The simplest and extreme response: Give
More information2015 年 4 月 25 日 GRE 考试 语文部分 真题回忆答案解析 小站教育独家出品 版权所有翻录必究
2015 年 4 月 25 日 GRE 考试 语文部分 真题回忆答案解析 小站教育独家出品 版权所有翻录必究 [4.25GRE 填空部分 ]: 1.The subject who were engaged in more difficult tasks deterioration in iheir performance over times, and therefore the need to concentrate
More informationINTRODUCTION. Key Words:
Original Acta Cardiol Sin 2007;23:247 53 The Efficacy and Safety of Angio-Seal Percutaneous Femoral Artery Closure Device after Diagnostic and Therapeutic Cardiac Catheterizations A Single Center s Experience
More informationDietary Guidelines for Chinese Residents (2016): comments and comparisons
Wang et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2016 17(9):649-656 649 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus;
More informationPCI for Bifurcation Coronary Lesion
PCI for Bifurcation Coronary Lesion Bifurcation Lesions PCI is Challenging Higher acute complication Lower success rates Higher restenosis & TLR Restenosis Rate 21 ~ 57% TLR 8 ~ 43% Event Free Survival
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationInvasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years *
796 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn Invasive fungal
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationScientific Data Sharing Platform
Qingdao China-US Roundtable Conference on Scientific Data Sharing Healthy World 2020 Scientific Data Sharing Platform Depei Liu, MD, Ph.D. Chinese Academy of Medical Sciences 2009-3-23 1 I will discuss
More informationField Control Efficiency of a Microbial Seed Dressing Agent of Bacillus Strain on Soybean Fungal Root Rot
微生物学通报 JUN 0, 009, 36(6): 84~846 Microbiology tongbao@im.ac.cn 研究报告 009 by Institute of Microbiology, CAS Field Control Efficiency of a Microbial Seed Dressing Agent of Bacillus Strain on Soybean Fungal
More informationPulmonary Rehabilitation 肺康复 许灵玲
Pulmonary Rehabilitation 肺康复 许灵玲 Contents 目录 What s pulmonary rehabilitation? Who are the members of the Interdisciplinary Team? Who benefits from pulmonary rehabilitation? What s the goals of pulmonary
More information